Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvervimab (GC1102) Phase 1 in Chronic Hepatitis B
NCT02569372Phase 1Completed
- Sponsor
- GC Biopharma
- Start
- Nov 2015
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GC5103 in Chronic Hepatitis B (CHB) (8 arms), sponsored by GC Biopharma. Primary endpoints: Dose Limiting Toxicity at 7 weeks, Adverse events at 7 weeks and 1 more. Started Nov 2015; status: completed.
02
Drugs
GC5103
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02569372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569372.